secwatch.observer — SEC 8-K summary
======================================

Issuer:     MoonLake Immunotherapeutics (MLTX)
CIK:        0001821586
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0001821586-25-000016
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MoonLake Q2 cash $425M; Phase 3 HS readout expected Sept 2025
-------------------------------------------------------------

- R&D expenses Q2 $49.8M (up from $36.5M Q1) on trial ramp-up and BLA preparation.
- Cash & equivalents $425.1M; up to $500M non-dilutive debt facility from Hercules Capital.
- Phase 3 VELA (HS) top-line readout on track for ~September 2025; BLA submission planned mid-2026.
- Phase 2 LEDA (PPP) interim readout reported; primary readout expected Q4 2025.
- Cash runway extended into 2028 to support sonelokimab launch in 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821586/000182158625000016/0001821586-25-000016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821586/000182158625000016/mnlk-20250805.htm
  HTML page:      https://secwatch.observer/filing/0001821586-25-000016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer